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Abstract
A dose-escalating phase II trial studied masitinib, an oral tyrosine
kinase inhibitor, in 43 patients with rheumatoid arthritis. Masitinib
induced American College of Rheumatology (ACR)20, ACR50 and
ACR70 responses in 54%, 26% and 8% of patients, respectively.
A placebo group was not included. Thirty-seven per cent of the
patients withdrew before the 12-week end-point was reached,
primarily because of adverse events. These findings are the first on
the efficacy of tyrosine kinase inhibition in a sizeable population.
Future work should focus on delineating the tyrosine kinase that is
most important in maintaining rheumatoid activity and address
potential long-term toxicities such as gonadal insufficiency,
teratogenicity and cardiotoxicity.
Introduction
In the previous issue of Arthritis Research and Therapy,
Jacques Tebib and coworkers [1] present the results of an
open-label, uncontrolled, phase IIa trial of oral masitinib in
patients with rheumatoid arthritis (RA). Masitinib is a tyrosine
kinase inhibitor that was recently approved for veterinary use in
dogs with unresectable mast cell tumours [2]. Masitinib is
currently being developed for the treatment of gastrointestinal
stromal and other tumours, but the trial presented here is the
first report on the use of masitinib in non-oncological pathology.
The lead compound of such tyrosine kinase inhibitors is
imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp,
Basel, Switzerland). Imatinib is approved for the treatment of
chronic myeloid leukaemia, in which it inhibits a tyrosine
kinase produced by the bcr-abl fusion gene. In addition to the
tyrosin kinase produced by bcr-abl, imatinib inhibits the
tyrosine kinase signalling of other proteins, such as the
receptors of platelet-derived growth factor (PDGF), stem cell
factor and macrophage colony-stimulating factor, all of which
have been implicated in the pathogenesis of RA [3,4]. In
synovial fluid mononuclear cells derived from RA patients,
imatinib was found to attenuate tumour necrosis factor (TNF)-
α production [5]. Imatinib was also shown to induce mast cell
apoptosis in the rheumatoid synovium [6]. Synovial mast cells
produce tissue destructive proteases and pro-inflammatory
cytokines, most prominently TNF-α, and they therefore
represent an interesting and novel target in the treatment of
RA [7].
That imatinib has efficacy in RA has indeed been suggested
in preclinical models and in human patients [4,8]. A phase II
clinical trial of imatinib 400 mg/day in combination with
methotrexate in RA has been completed (ClinicalTrials.gov
identifier NCT00154336) [9], but the results of this trial have
not yet been published.
Masitinib in rheumatoid arthritis
Tebib and coworkers [1] present the first study of masitinib in
non-oncological pathology. Masitinib was given twice daily,
either at an initial dose of 3 mg/kg per day or 6 mg/kg per
day. Dose escalations were allowed during the 12-week
study period. Half of the RA patients included had previously
failed a TNF-α inhibitor.
American College of Rheumatology (ACR)20, ACR50 and
ACR70 responses were achieved in 54%, 26% and 8% of
the RA patients, respectively. With the higher initial masitinib
dose, the median time to achieve an ACR20 response was
29 days and to achieve an ACR 50 response was 73 days. It
should be noted, however, that the efficacy analysis of this
phase II study is hampered by the lack of a placebo group.
Thus, a significant proportion of the study population could
have improved by regression to the mean and other effects.
With regard to safety, 37% of the patients included in the
masitinib study withdrew before they reached the 12-week
end-point, primarily because of adverse events. The overall
incidence of adverse events was 91% and included rash
(30%), oedema (mainly of the face; 26%), nausea (23%) and
diarrhoea (18.6%). In 21% of individuals the adverse events
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were severe. In some RA patients who were followed beyond
week 12, however, no instances of rash, nausea, vomiting or
diarrhoea were reported, although oedema persisted in a
sizeable proportion.
Safety profile of tyrosine kinase inhibitors
The side-effect profile of masitinib appears to be similar to
that observed in preclinical models and those of other
tyrosine kinase inhibitors. The occurrence of diarrhoea with
this drug class can be explained by the pharmacological
activity on the stem cell factor receptor on Cajal cells in the
intestine [10], whereas oedema is linked to PDGF receptor
blockade in the periorbital region. The side effects were
similar in the canine masitinib study [2] and commonly
involved the gastrointestinal tract.
Several data suggest that tyrosine kinase inhibitors may have
adverse effects that were not addressed in the human
masitinib study. The canine study, for example, found hair loss
to be among the most common side effects of masitinib.
Stem cell factor and PDGF signalling pathways also appear
to regulate the postnatal formation of spermatogonial stem
cells and Leydig cells in rat testis [11]. When imatinib was
given to male rodents, it reduced the litter size and led to
permanently elevated serum levels of gonadotrophins,
indicating latent testicular effects. In female laboratory
animals, masitinib also reduced fertility. Imatinib has also
been associated with ovarian insufficiency in humans [12].
Preclinical studies have demonstrated that imatinib is
embryotoxic and causes defects of the skull bones.
Malformations after imatinib exposure raise concerns of
similar outcomes in human pregnancy [13]. Cardiac toxicity
has been demonstrated with masitinib in rodents and with
imatinib in clinical trials. Given the small study population, the
short observation period and the methodology - which was
inadequate for detecting the side effects discussed above - it
is premature to conclude that masitinib is safe.
Conclusions
Despite its preliminary nature, the results of the human
masitinib trial are important in several respects. They represent
the largest body of published data with regard to tyrosine
kinase inhibition as a novel therapeutic approach in RA and
they support clinically important roles for stem cell factor
signalling and for other tyrosine kinases in the rheumatoid
synovium. The results are also interesting with respect to the
treatment of other rheumatic diseases, because tyrosine
kinase antagonists are currently being investigated in the
treatment of scleroderma and other fibrotic conditions.
Future investigations should address potential differences in
the efficacy and safety profile of masitinib, imatinib and other
tyrosine kinase inhibitors that are in clinical development.
Differences between the individual members of the drug
class may arise from their differential selectivity for the
tyrosine kinase receptors and should be addressed. With
regard to masitinib, long-term clinical toxicology should
address all target organs. The high frequency of reported
side effects does not support an important role for masitinib
in the first-line or second-line treatment of RA, but the
compound may enrich our therapeutic armamentarium in
recalcitrant cases.
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